Adam Weiner, Urologic Surgeon at Cedars-Sinai, shared a post on X about a paper he co-authored with colleagues published in JCO Precision Oncology:
“Prostate Cancer Focal Therapy Biomarker.
Title: Genomic Biomarker for Prostate Cancer Focal Therapy: Post Hoc Assessment of a Phase II Clinical Trial
Authors: Adam B. Weiner, James A. Proudfoot, Mamdouh Aker, Michelle Cardenas, Samantha Gonzalez, Eileen Kelly, Elai Davicioni, Anthony E. Sisk Jr, Wayne G. Brisbane, Leonard S. Marks.
Read the full article from JCO Precision Oncology.
Focal therapy is gaining interest as a treatment option for prostate cancer that has fewer side effects compared to surgery or radiation But recurrence rates can be as high as 1 in 3 within 1-2 years.
Currently, there is no biomarker to determine who is at high risk of early recurrence.
To that end, we took advantage of a prospective trial of patients who received focal therapy.
Title: Cryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes
Authors: Mamdouh N. Aker, Wayne G. Brisbane, Lorna Kwan, Samantha Gonzalez, Alan M. Priester, Adam Kinnaird, Merdie K. Delfin, Ely Felker, Anthony E. Sisk, David Kuppermann, Leonard S. Marks.
Read the full article from Cancer Medicine.
We sent off 108 tumors from biopsy for genomic testing to see if the genomic test was associated with recurrence.
We found that patients with a Decipher score>0.45 were at a much greater risk of recurrence.
Ongoing work is needed to validate, but this moves the needle on biomarkers for patients considering focal therapy.
Thanks to mentor Dr. Marks and collaborators at Decipher by Veracyte, Elai Davicioni.
Let’s keep working to improve precision care for our patients with prostate cancer.”
Read more posts featuring Adam Weiner on OncoDaily.
